Leadership

Dr. Antonin “Tony” De Fougerolles

Tony has over 20 years of biotech R&D experience in building out drug pipelines, and he has played a key role in developing and successfully advancing 3 new drug modalities towards the market (RNAi, modified mRNA, single domain antibodies) and in helping build several multi-billion dollar companies from start-up stage. Prior to joining Evox, Tony was CSO of Ablynx, where he led the company’s non-clinical R&D operations and played a key role in the approval of the 1st single domain antibody drug, caplacizumab. Prior to Ablynx, Tony was founding CSO at Moderna pioneering modified mRNA as a new therapeutic and vaccine modality and is an inventor of the mRNA chemistry and LNP delivery technology that forms the basis of both approved covid-19 mRNA vaccines, CSO of antibody-based immuno-oncology company Tolerx Inc, and VP Research at Alnylam where he helped develop RNAi as a new therapeutic modality including overseeing the development of the1st approved RNAi delivery system and several approved RNAi drugs including inclisiran. Also, Tony has been Principal Investigator on over $80m in grants, has over 60 scientific publications, and is an inventor on over 100 issued U.S. patents. He also serves on the Board of Walking Fish Therapeutics and is an advisor to MiNA Therapeutics and LIfT BioSciences. Tony earned his Ph.D. in Immunology from Harvard University.

Dr. Per Lundin

Dr. Per Lundin is Co-Founder & Chief Business Officer of Evox Therapeutics Ltd. He has ~15 years’ experience founding, leading and advising biotech companies developing advanced therapies. Prior to co-founding and building out Evox, he founded and led IsletOne Therapeutics, a cell therapy company developing allogeneic cell therapies for autoimmune and inflammatory diseases, and ultimately sold the business in a PE-led trade sale. Dr Lundin serves as non-executive director of AAV gene therapy company Combigene (Nasdaq First North: COMBI) and board director of Juvenile Diabetes Research Foundation UK (JDRF UK). He is a qualified European Patent Attorney with extensive business development and licensing experience; he earned his PhD from the Karolinska Institute, his Master of Science in Biotechnology Engineering from the Royal Institute of Technology, and his Master of Business Administration from Stockholm University School of Business.

Kerry Jaycock

Kerry is a strategic and commercially-focused leader with significant experience in business change and transformation. Motivated by a passion to drive the culture and ethos of a company, as Head of HR at Centrica Customer Services she enabled the organisation to effectively engage with both their employees and with key audiences. With the ability to influence and build strong relationships at all levels across organisations, oversee and project manage large-scale restructuring and organisational change, Kerry is motivated to deliver through values, employee engagement and communication.

Dave Carter

Dave is Head of Research at Evox Therapeutics. He has over 20 years’ experience working on pioneering, multidisciplinary applied research projects. Prior to joining Evox, he led an exciting research team that focused on extracellular vesicles as a Professor at Oxford Brookes University where he secured over £1m in grant funding and published more than 50 peer-reviewed articles. He was an active member of the International Society for Extracellular Vesicles and co-founder and first president of the UK Society for Extracellular Vesicles. His passion for exosomes brought him to Evox in 2021, where he has since supported the development of the DeliverEX platform and contributed to several pipeline projects in a matrix approach. Dave obtained his PhD from the University of Cambridge where he provided the first direct in vivo demonstration that enhancers and promoters physically interact to regulate gene expression. He also spent a year at the Sanger Centre, contributing important mapping data for the Human Genome Project.

Andrew Splevins

Andrew is Head of CMC at Evox Therapeutics. He brings over 15 years of development experience in biologic-based drug modalities. His high-performance leadership is complemented by his expertise in all aspects of CMC including process development, vector and cell line design, and analytical and formulation development. This has aided the development and manufacture of exosome therapeutics in preparation for the clinic using in-house and external capabilities. Before joining Evox, Andrew led collaborative cross-functional teams at Syntaxin, later acquired by Ipsen, in support of R&D for first-in-class recombinant botulinum neurotoxins from early phase research stages through development into the clinic. He is committed to inspiring innovation and its application to CMC development for novel products – where no standard approaches currently exist – to overcome technical challenges. Andrew earned a PhD from the University of Sheffield in Structural Biology studying protein folding and residual structures within unfolded protein states.

Rupert Kenefeck

Rupert is Head of Translational Medicine at Evox Therapeutics. He is an accomplished leader with 14 years’ experience in the field of translational science. He began his career by exploring the functional impact of T-follicular help cells and co-stimulatory mechanisms in Type 1 Diabetes and Primary Immunodeficiency Disease. Rupert subsequently led translational teams at Immunocore and Molecular Partners where he supported the development of new treatments through pre-clinical and early clinical phases. Rupert is committed to enhancing patients’ lives and values the opportunity to identify novel approaches that address unmet medical needs. His dedication to this brought him to Evox Therapeutics, where he leads the translational department in the development of first-in-class exosome-based genetic medicines. Rupert obtained his PhD from the University of Nottingham where he performed translational studies to investigate immune responses associated with Helicobacter pylori infection and disease in the gastric niche.

Matthew Ryan

Matthew is Senior Director of Operations at Evox Therapeutics. He has over 25 years’ experience in building Quality and Operations related capabilities, with particular expertise in Advanced Therapies-based biopharma drug development. Matthew has further experience in manufacturing, analytics and release from early-stage biotechnology start up through to clinical trials and commercial scale cell and gene therapy product approvals. Prior to joining Evox, he held several roles at Oxford Biomedica (OXB) including Head of Quality and Head of QPs & Product Release. There he led the Quality Assurance, Quality Control and Validation functions during a period of rapid growth and facilities expansion, hosting multiple FDA and MHRA inspections leading to successful license approval outcomes. At OXB he was also lead Qualified Person (QP) for the viral vector component of the first U.S.-approved advanced therapy and lead QP for the UK release of the Oxford-AstraZeneca Covid-19 vaccine bulk during the pandemic. Matthew is a Chartered member of the Royal Society of Biology. He holds MScs in both Chemistry and Medicinal Biochemistry from The Ohio State University, and a Postgraduate Diploma in Industrial Pharmaceutical studies.

Bob Higton

Bob is Senior Finance Director at Evox Therapeutics. With over 16 years’ financial experience, including a decade in the UK biotech sector, Bob is an established finance leader. He has played a pivotal role at Evox since joining in 2018, driving finance to support the company’s strategy.

Before joining Evox, Bob worked at Circassia Pharmaceuticals plc (now NIOX Group plc) where he helped scale the company post-IPO, working on multiple successful acquisitions during his tenure.

As an expert finance director, Bob has nurtured a culture of excellence within his team, empowering colleagues to excel. His financial insights have guided Evox through the complexities of biotech finance, enabling decisions that foster innovation and maintain the company’s leading position.

Bob is an ACCA certified accountant and graduated from the Reed Business School in Accounting and Finance.